All In Biotech

Company · ARGX

argenx

Includes drugs filed under related and acquired sponsor names. Trials are searched under: argenx.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

2

2 still marketed

Novel approvals

1

Approvals since 2021

10

Originals and new uses

Phase 3 trials

30

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (3)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • EmpasiprubartARGX-117Phase 39 trials

    argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP

  • ARGX-119Phase 21 trial

    argenx · Spinal Muscular Atrophy (SMA)

  • ARGX-121Phase 21 trial

    argenx · Immunoglobulin A Nephropathy (IgAN)

Recruiting Phase 3 trials

Largest first.

Marketed drugs (2)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.